Lilly Announces Increased Access to Clinical Trials Data for Qualified Researchers
Eli Lilly and Company announced it will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com.
Eli Lilly and Company announced it will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com. This website, which houses data from several clinical trial sponsors, was created in support of ongoing efforts by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) to increase access to and transparency of clinical trial results with researchers around the world.
The new portal, www.clinicalstudydatarequest.com, differs from previous Lilly data-sharing sites in that access will only be granted after approval of a research proposal by an independent scientific review panel. Lilly will not be involved in the decisions made by the independent scientific review panel.
As part of Lilly's commitment to open access and transparency, the company established its own web site in January 2014 to facilitate researchers' requests for data from interventional clinical trials for approved medicines and indications. However, this website was an interim solution. Lilly will replace the current web site, www.lillyclinicalstudydata.com, with the newly announced www.clinicalstudydatarequest.com.
Lilly also provides information on and links to information about our clinical studies on www.LillyTrials.com. The website includes results of all Lilly-sponsored Phase II, Phase III and Phase IV clinical trials as well as observational trials of Lilly-marketed products conducted anywhere in the world that were initiated on or after October 15, 2002.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
